Possibilities and challenges for developing a successful vaccine for leishmaniasis
Open accessThe DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Abstract
Leishmaniasis is a vector-borne disease caused by different species of protozoan parasites of the genus Leishmania. It is a major health problem yet neglected tropical diseases, with approximately 350 million people worldwide at risk and more than 1.5 million infections occurring each year. Leishmaniasis has different clinical manifestations, including visceral (VL or kala-azar), cutaneous (CL), mucocutaneous (MCL), diffuse cutaneous (DCL) and post kala-azar dermal leishmaniasis (PKDL). Currently, the only mean to treat and control leishmaniasis is by rational medications and vector control. However, the number of available drugs is limited and even these are either exorbitantly priced, have toxic side effects or prove ineffective due to the emergence of resistant strains. On the other hand, the vector control methods are not so efficient. Therefore, there is an urgent need for developing a safe, effective, and affordable vaccine for the prevention of leishmaniasis. Although in recent years a large body of researchers has concentrated their efforts on this issue, yet only three vaccine candidates have gone for clinical trial, until date. These are: (i) killed vaccine in Brazil for human immunotherapy; (ii) live attenuated vaccine for humans in Uzbekistan; and (iii) second-generation vaccine for dog prophylaxis in Brazil. Nevertheless, there are at least half a dozen vaccine candidates in the pipeline. One can expect that, in the near future, the understanding of the whole genome of Leishmania spp. will expand the vaccine discovery and strategies that may provide novel vaccines. The present review focuses on the development and the status of various vaccines and potential vaccine candidates against leishmaniasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Macrophages manage to kill some of the phagocytozed parasites but also constitute a replicative niche [287,288].”
From Functions of ROS in Macrophages and Antimicrobial Immunity (2021) · cites this paper as [288]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Akira, S., & Takeda, K. (2004) · Nature reviews. Immunology · doi:10.1038/nri1391 · Cited by 8,312 · cited 1×
“major murine model, the absence of TLR2 led to an increased number of cutaneous lesions [37] and TLR2 and 3 were involved in the phagocytosis of L.”
BackgroundLeishmaniasis Worldwide and Global Estimates of Its Incidence
Alvar, J., Vélez, I. D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., Boer, M. D., & the WHO Leishmaniasis Control Team (2012) · PLoS ONE · doi:10.1371/journal.pone.0035671 · Cited by 5,141 · cited 1×
“Approximately 12 million people are infected with a species of Leishmania at any given time point [1].”
BackgroundKorn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873 · cited 2×
“It may be because these cells are involved in the recruitment, migration and activation of neutrophils [18].”
BackgroundCD4+CD25+ regulatory T cells control Leishmania major persistence and immunity
Belkaid, Y., Piccirillo, C. A., Mendez, S., Shevach, E. M., & Sacks, D. L. (2002) · Nature · doi:10.1038/nature01152 · Cited by 1,725 · cited 1×
“The presence of these cells may, however, precondition the skin for survival of Leishmania parasites and favour long-term parasite survival [27].”
BackgroundThe Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases
Davis, B. K., Wen, H., & Ting, J. P.-Y. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101405 · Cited by 1,618 · cited 1×
“NLRs and inflammasomes are linked to several autoimmune and inflammatory diseases as well as infections [46].”
BackgroundIL-22 Increases the Innate Immunity of Tissues
Wolk, K., Kunz, S., Witte, E., Friedrich, M., Asadullah, K., & Sabat, R. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.007 · Cited by 1,359 · cited 1×
“IL-22 is also produced by Th17 cells, and to a lesser extent by natural killer and Th1 cells [18], which are particularly involved in immunity in epithelial and mucosal levels [19].”
BackgroundThe Regulation of Immunity to Leishmania major
Reiner, S. L. (1995) · Annual Review of Immunology · doi:10.1146/annurev.immunol.13.1.151 · Cited by 1,297 · cited 1×
“However, current knowledge is mostly based on experimental animal models and cannot be extrapolated to humans or dogs [7].”
BackgroundLeishmaniasis: complexity at the host–pathogen interface
Kaye, P., & Scott, P. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2608 · Cited by 988 · cited 1×
“Since the immune defence against Leishmania infection and cure from disease involves adaptive and innate cellular immune responses, it is perceivable that immunity depends on pathogen-specific CD4+ and CD8+ T cells with regulatory as well as effector functions of phagocytic effector cells [116, 117].”
BackgroundFunction of Nod‐like receptors in microbial recognition and host defense
Franchi, L., Warner, N., Viani, K., & Nuñez, G. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00734.x · Cited by 903 · cited 1×
“NLRs cooperate with TLRs and regulate inflammatory and apoptotic response and play key roles in the regulation of innate immune response [45].”
BackgroundOrigin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells
Merad, M., Ginhoux, F., & Collin, M. (2008) · Nature Reviews Immunology · doi:10.1038/nri2455 · Cited by 850 · cited 1×
“cialized type of dendritic cells (DC) only present in the skin and skin-draining lymph nodes [62].”
Background
Cited by
Functions of ROS in Macrophages and Antimicrobial Immunity
Herb, M., & Schramm, M. (2021) · Antioxidants · doi:10.3390/antiox10020313 · Cited by 633
Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need
Field, M. C., Horn, D., Fairlamb, A. H., Ferguson, M. A. J., Gray, D. W., Read, K. D., De Rycker, M., Torrie, L. S., Wyatt, P. G., Wyllie, S., et al. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.193 · Cited by 421
Leishmaniasis in humans: drug or vaccine therapy?
Ghorbani, M., & Farhoudi, R. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s146521 · Cited by 355
Macrophage Polarization in Leishmaniasis: Broadening Horizons
Tomiotto-Pellissier, F., Bortoleti, B. T. D. S., Assolini, J. P., Gonçalves, M. D., Carloto, A. C. M., Miranda-Sapla, M. M., Conchon-Costa, I., Bordignon, J., & Pavanelli, W. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02529 · Cited by 224
“Both of these factors are closely related to the clinical forms of leishmaniasis (20, 21).”
BackgroundLeishmania Vaccines Entered in Clinical Trials: A Review of Literature
Moafi, M., Rezvan, H., Sherkat, R., & Taleban, R. (2019) · International Journal of Preventive Medicine · doi:10.4103/ijpvm.ijpvm_116_18 · Cited by 138
“Whole‐killed Leishmania vaccines have low cost and achieved the first senior success in animal modeling; nevertheless, none of the human vaccines in this subgroup has accomplished the World Health Organization (WHO) validity.[12] For instance, Leishvaccine, which comprised whole‐killed promastigotes of Leishmania amaz…”
Influential
Metadata
- Authors
- Srivastava, S., Shankar, P., Mishra, J., & Singh, S.
- Affiliations
- All India Institute of Medical Sciences (IN)
- Corresponding author
- Singh, Sarman
- Venue
- Parasites & Vectors
- Published
- 2016-05-12
- Volume
- 9
- Issue
- 1
- Pages
- 277-277
- ISSN
- 1756-3305 (ISSN-L)
- PMC
- PMC4866332
- OpenAlex
- W2385321340
- Cited by
- 201
- References
- 139
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 18 · 2023: 15 · 2022: 22 · 2021: 34 · 2020: 20 · 2019: 22 · 2018: 18 · 2017: 25 · 2016: 2
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Parasites & Vectors (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- European Commission, FP7 (Grant No. 602773 (HEALTH-F3-2013-602773) under the category FP7-Health-2013-Innovation)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Research on Leishmaniasis Studies
- Health Sciences › Medicine › Infectious Diseases › Leprosy Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › Brucella: diagnosis, epidemiology, treatment
- Keywords
- leishmaniasis, Leishmania, vaccine development, vaccine candidate, neglected tropical diseases, visceral leishmaniasis, cutaneous leishmaniasis, mucocutaneous leishmaniasis, diffuse cutaneous leishmaniasis, post-kala-azar dermal leishmaniasis, live attenuated vaccine, inactivated vaccine, whole genome sequencing, drug resistance
- MeSH terms
- Animals, Dog Diseases, Dogs, Humans, Leishmania, Leishmaniasis, Vaccines, Attenuated, Vaccines, Inactivated, Leishmaniasis Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Possibilities and challenges for developing a successful vaccine for leishmaniasis. https://app.cochat.ai/papers/10.1186/s13071-016-1553-y
- The paper
- Srivastava, S., Shankar, P., Mishra, J., & Singh, S. (2016). Possibilities and challenges for developing a successful vaccine for leishmaniasis. Parasites & Vectors. https://doi.org/10.1186/s13071-016-1553-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
